Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

Objective Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains/related conditions of psoriatic arthritis (PsA).Methods Post hoc analyses used data from DISCOVER-2 (NCT03158285) biologic/Janus-kinase inhi...

Full description

Bibliographic Details
Main Authors: Laure Gossec, Peter Nash, Philip J Mease, Emmanouil Rampakakis, Laura C Coates, Philip S Helliwell, Alexa P Kollmeier, Xie L Xu, May Shawi, Miriam Zimmermann, Natalie J Shiff
Format: Article
Language:English
Published: BMJ Publishing Group 2024-03-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/10/1/e003977.full

Internet

https://rmdopen.bmj.com/content/10/1/e003977.full

Similar Items